200 related articles for article (PubMed ID: 16151393)
1. Upping the ante on antibodies.
Baker M
Nat Biotechnol; 2005 Sep; 23(9):1065-72. PubMed ID: 16151393
[TBL] [Abstract][Full Text] [Related]
2. Europe caught in innovation quagmire.
Mitchell P
Nat Biotechnol; 2005 Sep; 23(9):1029. PubMed ID: 16151378
[No Abstract] [Full Text] [Related]
3. Flexibility--the guiding principle for antibody manufacturing.
Carson KL
Nat Biotechnol; 2005 Sep; 23(9):1054-8. PubMed ID: 16151390
[TBL] [Abstract][Full Text] [Related]
4. IPO floodgates unlikely to open after Ark floatation.
Louët S
Nat Biotechnol; 2004 Apr; 22(4):367-8. PubMed ID: 15060538
[No Abstract] [Full Text] [Related]
5. Monoclonal antibody successes in the clinic.
Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
[TBL] [Abstract][Full Text] [Related]
6. Sequence-based protein kinase inhibition: applications for drug development.
Wexler ID; Niv MY; Reuveni H
Biotechniques; 2005 Oct; 39(4):575-6. PubMed ID: 16235571
[No Abstract] [Full Text] [Related]
7. Toward biosimilar monoclonal antibodies.
Schneider CK; Kalinke U
Nat Biotechnol; 2008 Sep; 26(9):985-90. PubMed ID: 18779806
[No Abstract] [Full Text] [Related]
8. Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Emerging and early stage company showcase pre-conference symposium.
Razvi ES
IDrugs; 2005 Oct; 8(10):796-8. PubMed ID: 16254794
[No Abstract] [Full Text] [Related]
9. Foundation Review: Transgenic animals and their impact on the drug discovery industry.
Dunn DA; Pinkert CA; Kooyman DL
Drug Discov Today; 2005 Jun; 10(11):757-67. PubMed ID: 15922934
[TBL] [Abstract][Full Text] [Related]
10. Genentech awarded critical antibody patent.
Robertson D
Nat Biotechnol; 2002 Feb; 20(2):108. PubMed ID: 11821843
[No Abstract] [Full Text] [Related]
11. The patentability of antibodies in the United States.
Lu DL; Collison AM; Kowalski TJ
Nat Biotechnol; 2005 Sep; 23(9):1079-80. PubMed ID: 16151395
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy: cursed or inching towards credibility?
Branca MA
Nat Biotechnol; 2005 May; 23(5):519-21. PubMed ID: 15877060
[No Abstract] [Full Text] [Related]
13. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
Fitzgerald GA
Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
[TBL] [Abstract][Full Text] [Related]
14. New opportunities for biocatalysis: making pharmaceutical processes greener.
Woodley JM
Trends Biotechnol; 2008 Jun; 26(6):321-7. PubMed ID: 18436317
[TBL] [Abstract][Full Text] [Related]
15. New pharma-biotech company formation in India.
Saberwal G
Nat Biotechnol; 2006 May; 24(5):499-501. PubMed ID: 16680124
[No Abstract] [Full Text] [Related]
16. Prologue: chirality in the pharmaceutical industry.
Caldwell J; Berova N; McConnell O
Chirality; 2007 Sep; 19(9):657. PubMed ID: 17657706
[No Abstract] [Full Text] [Related]
17. High throughput screening: early successes indicate a promising future.
Fox S; Wang H; Sopchak L; Khoury R
J Biomol Screen; 2001 Jun; 6(3):137-40. PubMed ID: 11689109
[No Abstract] [Full Text] [Related]
18. BTJ Forum: Biotech in the financial crisis.
Biotechnol J; 2009 Aug; 4(8):1108-10. PubMed ID: 19685461
[No Abstract] [Full Text] [Related]
19. Building biomanufacturing capacity--the chapter and verse.
Kamarck ME
Nat Biotechnol; 2006 May; 24(5):503-5. PubMed ID: 16680126
[TBL] [Abstract][Full Text] [Related]
20. Bad medicine.
Sheridan C
Nat Biotechnol; 2007 Jul; 25(7):707-9. PubMed ID: 17621284
[No Abstract] [Full Text] [Related]
[Next] [New Search]
